UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended				6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash flows from operating activities:
Net (loss) income	$ (11,703)	$ (865)	$ (8,864)	$ (13,018)		$ 18,306	$ (30,487)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization						1,297	1,690
Loss on disposal of property and equipment						0	478
Remeasurement of acquisition-related contingent consideration						3,327	2,384
Remeasurement of financing-related contingent consideration						435	496
Amortization of debt discount and debt issuance costs						4,835	4,424
Change in deferred tax and income tax deferred charge						(4,582)	1,333
Stock-based compensation expense						1,705	177
Gain on the disposition of the hospital products	0		0		$ (45,760)	(45,760)	0
Loss on deconsolidation of subsidiary						0	1,750
Other adjustments						306	(667)
Net changes in assets and liabilities
Accounts receivable						8,281	2,026
Inventories						(1,352)	2,465
Prepaid expenses and other current assets						1,759	(1,859)
Research and development tax credit receivable						2,036	(749)
Accounts payable & other current liabilities						(4,051)	259
Accrued expenses						(6,625)	(2,379)
Earn-out payments for contingent consideration in excess of acquisition-date fair value						(5,323)	(8,640)
Royalty payments for contingent consideration payable in excess of original fair value						(866)	(1,374)
Other assets and liabilities						(3,337)	(1,399)
Net cash used in operating activities						(29,609)	(30,072)
Cash flows from investing activities:
Purchases of property and equipment						(33)	(29)
Proceeds from the disposal of property and equipment						0	154
Proceeds from the disposition of the hospital products						17,250	0
Proceeds from sales of marketable securities						30,075	57,242
Purchases of marketable securities						(124,254)	(23,814)
Net cash (used in) provided by investing activities						(76,962)	33,553
Cash flows from financing activities:
Proceeds from the February 2020 private placement						60,570	0
Proceeds from the May 2020 public offering						116,924	0
Proceeds from stock option exercises and ESPP						2,006	123
Other financing activities, net						0	(109)
Net cash provided by financing activities						179,500	14
Effect of foreign currency exchange rate changes on cash and cash equivalents						406	47
Net change in cash and cash equivalents						73,335	3,542
Cash and cash equivalents at January 1,		$ 9,774		$ 9,325	$ 9,774	9,774	9,325	$ 9,325
Cash and cash equivalents at September 30,	$ 83,109		$ 12,867			83,109	12,867	$ 9,774
Supplemental disclosures of cash flow information:
Interest paid						6,469	6,469
Income taxes (refund) paid, net						$ (1,788)	$ 140